bpc 157 human clinical trial musculoskeletal injury Heal or Harm: Body Protective Compound-157 in the Gray Zone The “Wolverine” Drug – Ortho
Description
Medicare does not cover Prolotherapy
The peptide appears to enhance fibroblast recruitment, stimulate collagen deposition, and promote re-epithelialization through activation of the ERK1/2 signaling cascade
Thank you Nessy50
Its inhibition at the tissue level without systemic suppression represents a pharmacologically favorable profile for research applications where inflammation is driving local tissue damage
Heinz F
